Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
26-28 February, 2026
euroPLX 90 LisboneuroPLX 90 Lisbon
Not Confirmed
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Not Confirmed
Not Confirmed
02-03 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 February, 2026
euroPLX 90 LisboneuroPLX 90 Lisbon
Industry Trade Show
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Industry Trade Show
Not Confirmed
02-03 March, 2026
Digital content

23 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260223856924/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Fourth-Quarter-and-Year-Ended-December-31-2025

17 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260217315211/en/Summit-Therapeutics-to-Host-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Operational-Progress-Call-on-February-23-2026

30 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260130371236/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

30 Jan 2026
// PRESS RELEASE
https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx

29 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260129109846/en/Summit-Therapeutics-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy

09 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260109884241/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE